If you searched “CJC-1295 dosage,” you were probably hoping for a clean number: so many micrograms, so many times a week, done. This page will not give you that, and the reason is the whole point. CJC-1295 is not an FDA-approved medicine with an official label, and the version most people actually encounter is a gray-market injectable of unknown strength. A confident-looking dose printed on a website is not a protocol — it is a guess applied to an unverified product. What is genuinely useful, and what this page covers, is how dosing for a compound like this is decided, what changes it, and why the “standard internet dose” is the riskiest part of the whole equation.
How CJC-1295 dosing is actually determined
In any legitimate setting, the dose is not a property of the molecule — it is a property of the person. A prescriber works backward from the individual: their goal, their age, their baseline hormone levels, their tolerance, and how they respond over time. Two people handed the “same” peptide could reasonably be managed very differently, and a responsible provider expects to adjust over weeks rather than commit to a fixed figure on day one.
That is the opposite of how dosing circulates online, where a single number gets copied from forum to forum as if it were a settled fact. It never was. The number you see quoted is almost always an anecdote — someone’s self-experiment, repeated until it sounds official. Stripping a dose out of its clinical context (who set it, for whom, monitored against what) removes the only information that made it meaningful in the first place.
So the honest answer to “what’s the dose?” is: it depends, and it is decided by a clinician for a specific patient — not read off a page.
What actually changes the dose
Several real variables move the dosing picture, which is exactly why a one-size figure can’t exist.
The form: DAC vs no-DAC. This is the single biggest driver, and it trips up more people than anything else. CJC-1295 with DAC (a Drug Affinity Complex that tethers the peptide to albumin in the blood) has an estimated half-life of roughly 5.8–8.1 days, so a single injection keeps IGF-1 elevated for the better part of a week or more. CJC-1295 without DAC — frequently sold under the name Mod GRF 1-29 — clears in about half an hour and produces only a short pulse. These are not two strengths of the same thing; they are functionally different drugs with completely different dosing logic. Treating a long-acting albumin-bound compound the way you’d treat a 30-minute pulse (or vice versa) is a genuine safety problem, not a minor detail.
The goal and the indication. What someone is trying to achieve shapes any dosing decision. There is also a meaningful gap between the somatostatin-axis questions a clinician might actually evaluate and the recovery, sleep, or body-composition claims that drive most online interest — claims the human evidence does not establish. (Our benefits page separates what’s demonstrated from what’s inferred.)
Bodyweight and individual response. The original human study scaled doses by bodyweight, and individuals simply respond differently. A dose is something you titrate to a person’s measured response, not a constant you apply universally.
Monitoring results and tolerance. Where it is used legitimately, dosing is adjusted against follow-up labs and reported tolerability — not locked in. The dose at week eight may not be the dose at week one.
What the human trials actually showed
The most direct human evidence for CJC-1295 is a 2006 Phase 1 program by Teichman and colleagues, published in the Journal of Clinical Endocrinology and Metabolism. It is worth understanding what this study was and wasn’t.
It was a pair of randomized, placebo-controlled, double-blind trials in healthy adults aged 21–61. The design used escalating, weight-scaled single subcutaneous doses, followed in a second arm by a small number of weekly or biweekly doses, specifically to characterize the drug’s pharmacokinetics — how it moves through the body. After a single injection, blood GH rose in a dose-dependent way and IGF-1 stayed elevated for roughly 9–11 days; with repeated dosing, IGF-1 stayed above baseline for up to about four weeks. That long tail is the DAC form’s signature.
Two things matter here. First, this maps the shape of dosing — escalating, weight-scaled, and infrequent for the DAC form because of that multi-day half-life — without functioning as a take-home recipe. Second, and more importantly: the trial measured blood markers, not outcomes. It tracked GH and IGF-1 in the bloodstream. It did not measure muscle, fat, recovery, sleep quality, or how anyone looked. There has never been a completed Phase 2 or Phase 3 outcome trial establishing a real-world therapeutic dose for the goals people actually buy CJC-1295 for. So even the best human data tells you how the drug behaves pharmacologically — not what dose produces the results marketed online.
It’s also worth knowing that the later ConjuChem development program (a Phase 2 study in HIV-associated lipodystrophy) was discontinued, and development never reached registration. CJC-1295 has no approved label dose for anyone to point to as authoritative.
Why fixed internet protocols are unsafe
This is the part that matters most, so it’s stated plainly: the “standard” internet dose is unsafe even if the number itself were reasonable — because of what it’s being applied to.
CJC-1295 in the US is obtained gray-market. The vial in someone’s hand has not been verified for content or purity. Independent testing of research-chemical peptides routinely finds products that are underdosed, overdosed, degraded, or not what the label claims. When you take a precise-sounding microgram figure and apply it to a vial of unknown actual strength, the precision is an illusion — you don’t know how much active compound you’re delivering, in either direction. The right dose of the wrong or contaminated product is still wrong.
Layer onto that the absence of any monitoring in a self-dosing scenario. A legitimate dose is set against bloodwork and adjusted against response; “buy it and inject it” has neither. There is no one checking IGF-1, no baseline metabolic panel, no one watching for the things a prescriber would watch for. The Phase 2 program being halted is a reminder that growth-hormone-axis manipulation is not consequence-free and warrants medical oversight.
Note: A number that looks exact is not the same as a number that is safe. Precision in the dose means nothing when the concentration in the vial, the purity of the product, and the response of your body are all unknown. That combination — confident protocol, unverified product, no monitoring — is the specific harm here.
Monitoring and the red flags that matter
What does responsible oversight look like, and what should make you walk away?
A legitimate provider evaluates before dosing: history, goals, and baseline labs — typically IGF-1 read against age-adjusted reference ranges, alongside markers like fasting glucose and a metabolic panel to establish a safety baseline. Dosing is then set and re-checked against follow-up results, not fixed indefinitely.
The warning signs are the mirror image of that. Anyone offering a dose with no evaluation, no labs, and no follow-up — or a vendor who pairs “here’s the product” with “here’s the protocol” in the same breath — is skipping the entire part that makes dosing a medical decision rather than a gamble. “No consult, just buy and inject” is not convenience; it is the absence of the oversight the dose depends on. If you’re weighing a provider, our guide on how to choose a peptide clinic walks through what real evaluation should include.
US legal and approval status (2026)
Dosing can’t be separated from the question of whether there’s a legitimate route at all. CJC-1295 is not an FDA-approved drug — no approved application, no approved label, no agency-sanctioned indication, and no pharmacy can dispense it as a finished pharmaceutical.
Its US compounding status in 2026 is unsettled and genuinely contested across sources. Following the wider peptide reshuffle earlier in 2026, reporting differs on exactly where CJC-1295 now sits, and no reclassification has been finalized — the advisory-committee review and any formal rulemaking are still pending. Critically, that means there is no clean, settled legal compounding channel for CJC-1295 right now, and any change is not final until rulemaking concludes. This is current as of the date above and may shift. For the detailed, frequently-updated picture, see how to get CJC-1295 in the US and our breakdown of the 2026 FDA peptide reclassification; for the bigger framework, are peptides legal in the US?
The practical upshot for dosing: because there’s no clean legal supply, the “dosing” most people are really asking about is dosing of a gray-market product — which loops straight back to the central point. The compound’s pharmacology can be described; a safe at-home number for an unverified vial cannot.
The honest bottom line
CJC-1295 dosing is a clinical decision, individualized to a person and adjusted over time — not a fixed figure you can copy. The form (DAC vs no-DAC) changes everything, the human data maps pharmacokinetics rather than real-world outcomes, and the single most dangerous move is applying a confident internet protocol to a gray-market vial of unknown strength with no monitoring. If CJC-1295 is something you’re seriously considering, the responsible path is evaluation by a licensed provider who can assess you, weigh the unsettled legal status, and take ownership of any dosing decision — not a number from a forum.
Frequently asked questions
What is the standard CJC-1295 dose?
There isn't one. CJC-1295 is not an FDA-approved drug, so there is no official label dose. Where it is used at all, dosing is individualized by a prescriber based on the person's goal, age, labs, and response — and the DAC versus no-DAC form changes the picture entirely. Any single 'standard protocol' you see online is someone's anecdote, not a validated number.
Why won't this page just give me a dose in mg?
Because a printed milligram-and-frequency number on a public page functions as self-injection instructions for an unapproved, unregulated injectable of unknown concentration. CJC-1295 is obtained gray-market, where vial strength and purity vary widely, so a number that looks precise is misleading and potentially dangerous. Dosing belongs in a clinical setting with a real evaluation.
Does CJC-1295 with DAC and without DAC use the same dosing?
No — they behave very differently. The DAC (Drug Affinity Complex) form binds to albumin and has a half-life of roughly 6–8 days, so it is dosed far less often. The no-DAC form (often sold as Mod GRF 1-29) clears in about 30 minutes and produces only a brief pulse. Treating them as interchangeable is one of the most common and consequential mistakes.
What did the human trials use?
The main human evidence is a 2006 Phase 1 program (Teichman et al., JCEM) in healthy adults. It used escalating, weight-scaled single subcutaneous doses, then a small number of weekly or biweekly doses, to map the drug's pharmacokinetics. It measured blood GH and IGF-1, not body composition, and was never designed to establish a real-world 'use this dose' protocol.
How would a legitimate provider decide and monitor a dose?
A legitimate provider evaluates you first — history, goals, and bloodwork such as IGF-1 relative to age-adjusted ranges, plus baseline metabolic markers — then sets and adjusts dosing over time against those results. 'No evaluation, just buy and inject' is the warning sign, not the norm.